Cellectar Biosciences (CLRB) News Today → Next President (Not Trump. Not Biden.) (From The Freeport Society) (Ad) Free CLRB Stock Alerts $3.30 -0.03 (-0.90%) (As of 05/17/2024 08:53 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 17 at 2:10 AM | americanbankingnews.comQ2 2024 EPS Estimates for Cellectar Biosciences, Inc. Boosted by Analyst (NASDAQ:CLRB)May 16, 2024 | markets.businessinsider.comBuy Rating on Cellectar Biosciences Backed by Strong Clinical Data and Promising Drug PipelineMay 16, 2024 | marketbeat.comRoth Capital Equities Analysts Lift Earnings Estimates for Cellectar Biosciences, Inc. (NASDAQ:CLRB)Cellectar Biosciences, Inc. (NASDAQ:CLRB - Free Report) - Equities research analysts at Roth Capital raised their Q2 2024 earnings per share estimates for shares of Cellectar Biosciences in a research note issued on Tuesday, May 14th. Roth Capital analyst J. Aschoff now forecasts that the biopharMay 16, 2024 | americanbankingnews.comRoth Capital Weighs in on Cellectar Biosciences, Inc.'s FY2026 Earnings (NASDAQ:CLRB)May 15, 2024 | msn.comCellectar Biosciences, Inc. (NASDAQ:CLRB) Q1 2024 Earnings Call TranscriptMay 15, 2024 | marketbeat.comCellectar Biosciences, Inc. to Post FY2026 Earnings of $0.97 Per Share, Roth Capital Forecasts (NASDAQ:CLRB)Cellectar Biosciences, Inc. (NASDAQ:CLRB - Free Report) - Investment analysts at Roth Capital raised their FY2026 EPS estimates for Cellectar Biosciences in a report released on Tuesday, May 14th. Roth Capital analyst J. Aschoff now expects that the biopharmaceutical company will earn $0.97 per sMay 15, 2024 | finance.yahoo.comCellectar Biosciences Inc (CLRB) Q1 2024 Earnings Call Transcript Highlights: Strategic ...May 15, 2024 | finance.yahoo.comQ1 2024 Cellectar Biosciences Inc Earnings CallMay 14, 2024 | investorplace.comCLRB Stock Earnings: Cellectar Biosciences Misses EPS for Q1 2024May 14, 2024 | markets.businessinsider.comCellectar Biosciences Inc Loss At -$21.58 Mln In Q1May 14, 2024 | globenewswire.comCellectar Biosciences Reports Financial Results for Q1 2024 and Provides a Corporate UpdateMay 12, 2024 | americanbankingnews.comCellectar Biosciences (CLRB) Scheduled to Post Quarterly Earnings on TuesdayMay 8, 2024 | marketbeat.comCellectar Biosciences (CLRB) to Release Earnings on TuesdayCellectar Biosciences (NASDAQ:CLRB) will be releasing earnings before the market opens on Tuesday, May 14, Zacks reports.May 8, 2024 | globenewswire.comCellectar Biosciences to Present at the Guggenheim Healthcare Talks Radiopharmaceuticals DayMay 7, 2024 | globenewswire.comCellectar Biosciences to Announce First Quarter Financial Results and Host a Conference Call on Tuesday, May 14, 2024May 2, 2024 | morningstar.comCellectar Biosciences Inc CLRBApril 19, 2024 | seekingalpha.comCLRB Cellectar Biosciences, Inc.April 14, 2024 | marketbeat.comCellectar Biosciences, Inc. (NASDAQ:CLRB) Short Interest UpdateCellectar Biosciences, Inc. (NASDAQ:CLRB - Get Free Report) was the recipient of a large increase in short interest during the month of March. As of March 31st, there was short interest totalling 2,530,000 shares, an increase of 34.6% from the March 15th total of 1,880,000 shares. Based on an average daily trading volume, of 1,790,000 shares, the short-interest ratio is currently 1.4 days. Currently, 8.7% of the shares of the company are short sold.April 9, 2024 | marketbeat.comCellectar Biosciences (NASDAQ:CLRB) Stock Price Passes Above 50 Day Moving Average of $3.73Cellectar Biosciences (NASDAQ:CLRB) Stock Crosses Above Fifty Day Moving Average of $3.73March 29, 2024 | markets.businessinsider.comBuy Rating on Cellectar Biosciences Backed by Promising Drug Candidate and Solid FinancialsMarch 29, 2024 | nz.finance.yahoo.comJeremy Renner Sweetly Hugs Daughter Ava in Rare Photo as He Celebrates His 'Number One' on Her 11th BirthdayMarch 29, 2024 | finance.yahoo.comCellectar Biosciences, Inc. (NASDAQ:CLRB): When Will It Breakeven?March 28, 2024 | finance.yahoo.comQ4 2023 Cellectar Biosciences Inc Earnings CallMarch 27, 2024 | investorplace.comCLRB Stock Earnings: Cellectar Biosciences Beats EPS for Q4 2023March 27, 2024 | msn.comCellectar Biosciences FY 2023 Earnings PreviewMarch 27, 2024 | benzinga.comEarnings Preview For Cellectar BiosciencesMarch 27, 2024 | globenewswire.comCellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate UpdateMarch 20, 2024 | globenewswire.comCellectar Biosciences to Announce 2023 Year End Earnings Results and Host a Conference Call on Wednesday, March 27, 2024March 14, 2024 | globenewswire.comCellectar Biosciences to Present at the 36th Annual Roth ConferenceMarch 4, 2024 | globenewswire.comCellectar Biosciences Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of Iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck CancerFebruary 22, 2024 | benzinga.comCellectar Biosciences Stock (NASDAQ:CLRB), Short Interest ReportFebruary 15, 2024 | money.usnews.comCellectar Biosciences IncFebruary 12, 2024 | seekingalpha.comCellectar Biosciences: A Shoestring Opportunity You're About To MissFebruary 7, 2024 | finance.yahoo.comCellectar Biosciences to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceJanuary 25, 2024 | finance.yahoo.comCellectar Biosciences Announces Tranche A Warrants Fully Exercised, Providing Proceeds of $44.1 MillionJanuary 23, 2024 | investing.comCellectar Biosciences Inc (CLRB)January 22, 2024 | msn.comCellectar stock climbs 8% on results for CNS malignancy therapyJanuary 22, 2024 | finance.yahoo.comCellectar Biosciences Reports Complete Central Nervous System (CNS) Clearance in Relapsed/Refractory Waldenstrom’s Macroglobulinemia PatientJanuary 16, 2024 | finance.yahoo.comCellectar Biosciences Broadens Pipeline with Targeted Alpha Therapy (TAT) for Solid Tumors and Releases Promising Preclinical DataJanuary 12, 2024 | finance.yahoo.comCellectar Biosciences to Host Conference Call with Texas Oncology Hematologist M. Yair Levy, M.D. on January 19, 2024 to Discuss Iopofosine I 131 Pivotal Topline ResultsJanuary 8, 2024 | marketwatch.comCellectar Biosciences Shares Hit 52-Week High After Positive Iopofosine I ResultsJanuary 8, 2024 | msn.comWhy Is Cancer-Focused Cellectar Biosciences Stock Trading Higher Today?January 8, 2024 | marketwatch.comCellectar Biosciences' Iopofosine I Meets Primary Endpoint in Rare Blood Cancer StudyJanuary 8, 2024 | reuters.comCellectar's blood cancer therapy succeeds in trialJanuary 8, 2024 | msn.comCellectar Biosciences gains on pivotal data for radiotherapyJanuary 8, 2024 | msn.comWhy Is Cellectar Biosciences (CLRB) Stock Up 16% Today?January 8, 2024 | finance.yahoo.comCellectar Biosciences Announces Positive Topline Data Achieving Primary Endpoint in Pivotal Clinical Study of Iopofosine I 131 in Waldenstrom’s MacroglobulinemiaJanuary 3, 2024 | finance.yahoo.comCellectar Biosciences to Announce Top-line Data from WM Pivotal Trial on January 8, 2024December 19, 2023 | finance.yahoo.comCellectar Biosciences Expands Iopofosine I 131 Collaboration with Wisconsin Alumni Research FoundationDecember 12, 2023 | finance.yahoo.comCellectar Biosciences Strengthens Intellectual Property Protection for its PDC Platform Get Cellectar Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CLRB and its competitors with MarketBeat's FREE daily newsletter. Email Address The Overlooked Retirement Asset You Probably Don’t Own (Ad)4 out of 5 Americans believe we’re on the brink of a retirement crisis. Luckily, in these unprecedented times, we have an unprecedented solution. Once considered a “fringe” investment, the crypto market is now taking the world by storm. Click here to access the Crypto Retirement Blueprint now. CLRB Media Mentions By Week CLRB Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CLRB News Sentiment▼0.630.42▲Average Medical News Sentiment CLRB News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CLRB Articles This Week▼181▲CLRB Articles Average Week Get Cellectar Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CLRB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: RZLT News ABEO News IMUX News CRVS News ADAG News FGEN News CTXR News PMVP News RLMD News ACET News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CLRB) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldUrgent Nvidia WarningAltimetryDoes this make you sick?Allegiance GoldThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarShocking: One AI startup's revenue could surge 4,735%Manward PressGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cellectar Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
